Determinants of growth after kidney transplantation in prepubertal children

Julia Grohs 1 · Rainer-Maria Rebling 1 · Kerstin Froede 1 · Kristin Hmeidi 1,2 · Leo Pavičić 3 · Jutta Gellermann 4 · Dominik Müller 4 · Uwe Querfeld 4 · Dieter Haffner 1,2 · Miroslav Živičnjak 1

Received: 16 September 2020 / Revised: 23 November 2020 / Accepted: 5 January 2021 / Published online: 23 February 2021 © The Author(s) 2021

Abstract

Background Short stature is a frequent complication after pediatric kidney transplantation (KT). Whether the type of transplantation and prior treatment with recombinant human growth hormone (GH) affects post-transplant growth, is unclear.

Methods Body height, leg length, sitting height, and sitting height index (as a measure of body proportions) were prospectively investigated in 148 prepubertal patients enrolled in the CKD Growth and Development study with a median follow-up of 5.0 years. We used linear mixed-effects models to identify predictors for body dimensions.

Results Pre-transplant Z scores for height (−2.18), sitting height (−1.37), and leg length (−2.30) were reduced, and sitting height index (1.59) was increased compared to healthy children, indicating disproportionate short stature. Catch-up growth in children aged less than 4 years was mainly due to stimulated trunk length, and in older children to improved leg length, resulting in normalization of body height and proportions before puberty in the majority of patients. Use of GH in the pre-transplant period, congenital CKD, birth parameters, parental height, time after KT, steroid exposure, and transplant function were significantly associated with growth outcome. Although, unadjusted growth data suggested superior post-transplant growth after (pre-emptive) living donor KT, this was no longer true after adjusting for the abovementioned confounders.

Conclusions Catch-up growth after KT is mainly due to stimulated trunk growth in young children (<4 years) and improved leg growth in older children. Beside transplant function, steroid exposure and use of GH in the pre-transplant period are the main potentially modifiable factors associated with better growth outcome.

Keywords Chronic kidney disease · Children · Kidney transplantation · Growth · Body proportions · CKD-MBD

Introduction

Growth failure is frequent in children with stage 5 chronic kidney disease (CKD 5). Its etiology is multifactorial and includes intrauterine growth restriction, malnutrition, mineral and bone disorder, aciddosis, fluid and electrolyte abnormalities, and disturbances of the somatotropic hormone axis [1]. Registry data shows that growth outcome has improved considerably in these patients during recent decades [2, 3]. However, reduced adult height is still noted in approximately 40% of children with CKD 5; it not only affects quality of life, self-esteem, and social rehabilitation, but is also associated with excessive mortality in these patients [3–8].

Kidney transplantation (KT) resolves many of the metabolic and endocrine disorders contributing to uremic growth failure, but rarely results in substantial catch-up growth [5, 9, 10]. Young age at KT, transplant function and steroid exposure are important factors influencing post-transplant growth, but they only partly explain the large variability of growth outcome [5, 9, 11–14]. Whether the type of transplantation (living versus deceased donor; pre-emptive KT versus prior dialysis) or treatment with recombinant human growth hormone (GH) prior to KT impact on post-transplant growth are largely
unknown [5, 10, 15]. Previous analyses mainly coming from patient registries did not include detailed data on factors affecting growth, such as abnormal birth history, low parental height, pubertal status, and medication use (i.e., steroids, GH) and could therefore not adjust for these variables [13, 16–19]. Finally, CKD 5 in children is associated with more severe impairment of leg growth in comparison to trunk growth resulting in disproportionate short stature [13, 19, 20]. We hypothesized that KT stimulates the growth of linear body segments (trunk and legs) differentially in toddlers and older children and that its effects on body proportions are therefore age dependent.

To this aim, we assessed post-transplant changes in linear body dimensions (height, sitting height, and leg length), and the ratio of trunk length to total body height (sitting height index) as a measure of body proportion and its determinants in 148 prepubertal children enrolled in the prospective CKD Growth and Development Study.

Methods

Study design and population

From May 1998 until November 2019, a total of 947 children with CKD stages 3–5D and after KT were enrolled in the CKD Growth and Development Study, which is a prospective, observational cohort study performed at two pediatric nephrology centers in Germany (Hannover Medical School and Charité Universitätsmedizin Berlin). Patients are followed up at yearly intervals for clinical, biochemical and anthropometric assessment as previously described [19]. The study was approved by the local ethics committees, and research was performed in accordance with the declaration of Helsinki. Study participants and/or their parents gave their consent prior to participation.

For the present analysis, all first-time graft recipients, transplanted before the age of 8 years with a functional kidney transplant and with at least one valid follow-up visit were included. Patients with height-affecting skeletal abnormalities and/or severe locomotor dysfunction (n = 16) were excluded. All follow-up visits were included unless the patient reached age of 12 years to avoid bias of puberty. Thus, data from 148 patients (66% male), who underwent 722 annual measurements, with a median follow-up of 5.0 years (IQR, 3–7 years) could be included in the analysis (Table 1).

Children’s personal health care records were used to obtain data on gestational age, umbilical cord artery pH, birth weight, and length. Attainment of CKD 5 was defined by initiation of dialysis or pre-emptive KT. The prescribed dietary intake was in accordance with targeted requirements and estimated glomerular filtration rate (eGFR) was assessed by the Schwartz formula [21]. Newborns were classified as small for gestational age (SGA) if birth weight or length was < 10th percentile according to national growth standards [22]. Primary immunosuppressive protocols included daily prednisolone treatment. Prednisolone dosage was generally tapered down by week 8 to 4 mg/m²/day. From 2007, in cases of stable graft function and lack of rejection, patients were regularly weaned off steroids between 6 and 12 months post KT. Overall, steroids were withdrawn in 18% of patients after a median period of 8 months (range 6–12 months). Indicators for the use of GH treatment in the pre- and post-transplant period were a height SD score (SDS) < −2.0 and a height velocity < 25th percentile. Genetic target height was calculated from mid-parental height [23].

Anthropometry and outcome variables

Anthropometric measurements were performed by the same investigator (MŽ) as recommended by the International Biologic Program [24] with standardized equipment (Dr. Keller I Stadiometer, Limbach-Oberfrohna, Germany; Siber Hegner Anthropometer, Zürich, Switzerland) as previously described [13]. The sitting height index was calculated as the ratio between sitting height and total body height [25]. SD scores (SDS) for each segment of linear growth were calculated using reference values from healthy children [26, 27].

Statistical analyses

Data is given as mean ± SD and/or 95% CIs unless otherwise indicated. All anthropometric data is presented as age- and sex-related SDS values. Distribution normality was evaluated by the Shapiro-Wilk test for each parameter. Previous studies demonstrated that both chronological age as well as duration and timing of growth affecting measures, like KT, impact on body growth in children with CKD 5 [5, 13, 20]. Therefore, measurements were grouped according to age cohorts (2 to 11 years) and time after KT using yearly intervals. This allowed us to create two sets of correlated outcomes for statistical analysis. A total of 722 annual measurements (mean 4.9 per child) were available.

Linear mixed-effects models were used to assess predictors (defined as factors and covariates) of growth outcome and calculate adjusted and non-adjusted mean Z scores for linear body dimensions and proportions. Factors: congenital CKD (yes versus no), pre-emptive KT versus prior dialysis, living versus deceased donor, SGA history (yes versus no), sex (female versus male), and prior GH treatment (yes versus no). Due to the low frequency of GH treatment after KT (4%) this parameter was not included in the statistical analysis. Covariates: age at CKD 5, age at KT, time after KT, birth weight for length, umbilical cord artery pH at birth, parental height, as well as steroid dosage, eGFR, bicarbonate, and hemoglobin levels after KT.
The SPSS MMX-repeated measurement procedure defined as Kronecker product covariance structures was used, where covariance matrices are adjusted to respective time scales: one time scale with origin defined by time of birth and the other scale with origin at the age at KT. Finding the best Kronecker product structure for our data required selecting models for each of the time repeated factors. An unstructured covariance matrix for age cohort paired with also unstructured time after KT was chosen. A cubic spline function was used in Figs. 1 and 2 for graphical presentation of linear growth. The standard statistical package SPSS for Windows, version 26.0 (IBM Corporation, New York, USA) was used for statistical calculations. Results were considered significant at a level of $p < 0.05$.

### Results

Key characteristics of the study cohort are given in Table 1. Median age at CKD 5 and KT was 2.8 years and 3.7 years, respectively. In agreement with the young age at the time of CKD 5, the majority of patients suffered from congenital CKD (79.1%) mostly related to congenital anomalies of the kidneys and urinary tract (48%), which probably explains the high proportion of boys (62.2%). Twenty-seven percent of patients were born SGA, and 35.1% and 29.3% of patients underwent pre-emptive and/or living donor KT, respectively. Growth hormone was commenced in the pre-transplant period in 33.8% of patients over a median period of 1.4 years (IQR 0.57–2.23), and discontinued at the time of KT in all patients. Mean eGFR and steroid-dosage was 59 ml/min per 1.73 m$^2$ and 0.1 mg/kg per day, respectively. Metabolic acidosis (bicarbonate < 22 mmol/L) and mild (hemoglobin < 12 g/dl) or moderate (hemoglobin < 10 g/dl) anemia was noted in 35.1%, 72.1%, and 14.9% of annual measurements, respectively.

| Table 1 Clinical characteristics of 148 prepubertal pediatric kidney transplant recipients |
|------------------------------------------------------------------------------------------------|
| Nonrepeated measurements$^a$ | % or median | IQR | Range | No. of patients |
| Male, % | 66.2 | | | 98 of 148 |
| Age at KT, years | 3.68 | 2.07–5.60 | 0.49–7.98 | 148 |
| Age at dialysis initiation, years | 1.96 | 0.59–4.16 | 0.01–7.81 | 98 of 148 |
| Age at CKD 5, years | 2.77 | 0.93–4.87 | 0.01–7.87 | 148 |
| Duration of dialysis, years | 1.02 | 0.43–1.85 | 0.01–4.75 | 98 |
| Pre-emptive KT, % | 35.1 | | | 52 of 148 |
| Living donor, % | 29.3 | | | 43 of 147 |
| Congenital CKD, % | 79.1 | | | 117 of 148 |
| SGA history, % | 27.4 | | | 37 of 135 |
| GH therapy before KT, % | 33.8 | | | 50 of 148 |
| Age at start of GH therapy, years | 1.93 | 1.22–4.03 | 0.27–6.31 | 50 |
| Duration of GH treatment, years | 1.40 | 0.57–2.23 | 0.11–5.39 | 50 |
| Genetic target height, SDS | −0.13 | −0.79–0.55 | −2.93–1.46 | 142 |

| Repeated measurements$^b$ | Estimated marginal mean | 95% CI | Range | No. of measurements |
| eGFR, mL/min per 1.73 m$^2$ | 59 | 55–63 | 5–191 | 666 |
| Steroid dosage, mg/kg per day | 0.098 | 0.086–0.109 | 0.00–0.67 | 710 |
| Plasma HCO$_3$-, mmol/L | 22.6 | 22.0–23.2 | 18.3–33.3 | 693 |
| Hemoglobin, g/dL | 11.2 | 11.0–11.4 | 6.5–15.3 | 706 |

$IQR$, interquartile range; $KT$, kidney transplantation; $CKD 5$, stage 5 chronic kidney disease; $SGA$, small for gestational age; $GH$, growth hormone; $SDS$, SD score; $eGFR$, estimated glomerular filtration rate

$^a$ Basic data (nonrepeated measurements) are given as median and interquartile range (25–75th percentile)

$^b$ Average values (estimated marginal means) during the observation period are based on all annual values, repeated measurements within the same individual (evaluated with the linear mixed model, random patients and age cohorts)

The body dimensions and proportions before kidney transplantation

Pre-transplant mean Z scores for all linear body dimensions were reduced: height $-2.18 \pm 1.08$, sitting height $-1.37 \pm 0.97$, leg length $-2.30 \pm 1.17$ (each $p < 0.001$ versus healthy children, Fig. 1a). Higher impairment of leg length compared to sitting height ($p < 0.001$) resulted in a markedly elevated sitting height index ($1.59 \pm 1.1$ SDS, $p < 0.001$ versus healthy children, Fig. 1b), indicating disproportionate short stature.
Changes of body dimensions and proportions after transplantation

The increase in standardized height was most pronounced during the early post-transplant years, and amounted to 0.53 SDS and 0.84 SDS at 2 and 5 years, respectively (each \( p < 0.01 \) versus baseline Fig. 1a). Accordingly, the percentage of patients with short stature (height \( \leq -2.0 \) SDS) decreased from 61.8% at baseline to 38.0% and 28.2% at 2 and 5 years, respectively (each \( p < 0.01 \)). The degree and timing of catch-up growth of linear body segments, i.e., trunk and legs, differed distinctly. Although both standardized leg and trunk length significantly increased during the first 2 years after KT (\( p < 0.01 \)), the increase in sitting height clearly exceeded that of leg length (0.68 SDS versus 0.41 SDS, \( p < 0.05 \)). Thereafter, no significant changes in sitting height SDS were noted, whereas standardized leg length continuously further increased resulting in sustained improvement of sitting height index (Fig. 1b). The latter reached the level of statistical significance from the 6th year onwards when compared to baseline values (Fig. 1b). Accordingly, the percentage of patients with abnormal body proportion, defined as sitting height index \( \geq 2 \) SDS, decreased from 35.8% at baseline to 20.6% at 5 years (\( p < 0.05 \)).

Age-related changes in body dimensions after KT are given in Fig. 1c. Two distinct age periods were noted, i.e., before and after 4 years of age, reflecting the transition from toddlerhood to preschool age. Sitting height SDS increased continuously before the age of 4 years, while leg length SDS decreased (each \( p < 0.05 \)) which explains the lack of catch-up growth in terms of body height and indicates progressive body disproportion. By contrast, a sustained increase in both standardized leg length and body height was noted after the age of 4 years (each \( p < 0.05 \), Fig. 1c) while sitting height SDS even decreased from 6 to 7 years of age, and remained constant thereafter indicating improvement of body proportions (each \( p < 0.05 \) for age cohort 5 and above versus age 4 years).

---

**Fig. 1** Post-transplant growth in 148 prepubertal children by the time after kidney transplantation (a, b), and by age cohorts (c). a mean Z scores for height, sitting height, and leg length. All linear body dimensions were significantly reduced at baseline compared to healthy children (each \( p < 0.001 \)), the degree of impairment significantly differed between the three body dimensions, indicating disproportionate stunting (each \( p < 0.001 \)); all body dimensions increased after kidney transplantation (KT), which became significant after the 1st year (sitting height) and 3rd year (leg length), respectively (each \( p < 0.05 \) versus baseline). The lower dotted horizontal line refers to the lower normal range (−2.0 SD score). b mean Z scores for sitting height index (ratio between sitting height and total body height) as a measure for body disproportion. Mean sitting height index was significantly increased before KT compared to healthy children and continuously decreased after KT which reached the level of statistical significance from the 6th year onwards. c mean Z scores for height, sitting height, and leg length by age cohorts. Catch-up growth after KT was mainly due to increased standardized sitting height in young children (<4 years), and improved standardized leg length in older children. The lower dotted horizontal line refers to the lower normal range (−2.0 SD score)
Determinants of post-transplant growth

Figure 2 illustrates non-adjusted post-transplant growth in specific subgroups. Impairment of linear body dimensions before KT was higher in children with SGA history compared to those with no SGA history (each \( p < 0.05 \)), but did not significantly differ in other subgroups. Linear body dimensions after KT significantly differed in all presented subgroups (each \( p < 0.05 \)) except for sitting height after pre-emptive KT compared to prior dialysis and for stature and leg length in male compared to female patients (Table 2).

In the multivariate analysis, congenital CKD was significantly associated with sitting height index (Table 3). Time after KT was associated with height, leg length, and sitting height index. The use of GH in the pre-transplant period, steroid dosage, eGFR, SGA history, and parental height were associated with all linear body dimensions after KT (each \( p < 0.05 \)), whereas birth weight for length and umbilical cord artery pH were associated with body height and sitting height only. By contrast, the type of KT, age at CKD 5 or KT, and hemoglobin and plasma HCO\(_3\) levels were not associated with growth outcome.
Table 2  Non-adjusted anthropometric parameters in subgroups of a cohort of 148 prepubertal kidney transplant recipients

| Parameter                  | Height SDS                  | p value | Leg length SDS                | p value | Sitting height SDS       | p value | Sitting height index SDS | p value |
|----------------------------|-----------------------------|---------|-------------------------------|---------|--------------------------|---------|--------------------------|---------|
| Congenital CKD             | −1.65 (−1.76 to −1.54)      | 0.000   | −1.85 (−1.97 to −1.73)        | 0.000   | −0.88 (−0.98 to −0.78)    | 0.031   | 1.50 (1.38 to 1.61)      | 0.000   |
| Others                     | −1.11 (−1.33 to −0.88)      |         | −1.24 (−1.48 to −1.00)        |         | −0.65 (−0.88 to −0.45)    |         | 0.88 (0.65 to 1.13)      |         |
| SGA                        | −1.73 (−1.92 to −1.54)      | 0.000   | −1.87 (−2.08 to −1.67)        | 0.000   | −1.04 (−1.21 to −0.86)    | 0.000   | 1.35 (1.15 to 1.55)      | 0.002   |
| non-SGA                    | −1.04 (−1.18 to −0.91)      |         | −1.21 (−1.36 to −1.07)        |         | −0.49 (−0.62 to −0.37)    |         | 1.03 (0.89 to 1.17)      |         |
| Pre-emptive KT             | −1.28 (−1.47 to −1.09)      | 0.028   | −1.44 (−1.65 to −1.24)        | 0.048   | −0.69 (−0.86 to −0.52)    | 0.08    | 1.11 (0.91 to 1.31)      | 0.105   |
| Previous dialysis          | −1.49 (−1.62 to −1.35)      |         | −1.65 (−1.79 to −1.50)        |         | −0.84 (−1.07 to −0.72)    |         | 1.27 (1.13 to 1.41)      |         |
| GH before KT               | −1.15 (−1.32 to −0.98)      | 0.000   | −1.30 (−1.48 to −1.12)        | 0.000   | −0.55 (−0.70 to −0.39)    | 0.000   | 1.11 (0.93 to 1.29)      | 0.090   |
| No GH before KT            | −1.62 (−1.77 to −1.47)      |         | −1.79 (−1.95 to −1.63)        |         | −0.98 (−1.12 to −0.84)    |         | 1.27 (1.11 to 1.42)      |         |
| Living donor KT            | −1.16 (−1.35 to −0.97)      | 0.000   | −1.35 (−1.56 to −1.15)        | 0.000   | −0.59 (−0.77 to −0.42)    | 0.000   | 1.09 (0.88 to 1.29)      | 0.038   |
| Deceased donor KT          | −1.61 (−1.74 to −1.47)      |         | −1.74 (−1.88 to −1.59)        |         | −0.94 (−1.06 to −0.82)    |         | 1.29 (1.15 to 1.43)      |         |
| Female                     | −1.33 (−1.51 to −1.17)      | 0.290   | −1.52 (−1.70 to −1.33)        | 0.575   | −0.68 (−0.83 to −0.52)    | 0.033   | 1.24 (1.06 to 1.41)      | 0.346   |
| Male                       | −1.43 (−1.59 to −1.28)      | 0.920   | −1.57 (−1.74 to −1.41)        | 0.86    | −1.00 to −0.71            | 1.08    | 1.14 (0.98 to 1.31)      |         |

Data are presented as SD score (SDS) values, estimated marginal means (95% confidence intervals). p values are based on the linearly independent pairwise comparisons among the estimated marginal means.

Discussion

The main findings of our study suggest that catch-up growth after KT in young children (< 4 years) is mainly due to stimulated trunk growth and improved leg growth in older children, resulting in normalization of body height and proportions before puberty in the vast majority of patients. In addition, the pre-transplant period, congenital CKD, birth parameters, and parental height were significantly associated with growth in the pre-transplant period, congenital CKD, birth parameters, and parental height were significantly associated with growth. Although unadjusted growth data suggested superior post-transplant growth in patients with prior GH treatment, these differences were not significant in the multivariate analysis. The percentage of patients with normal height (≥ 2 SD) increased from 0.5 to 0.7 SDS within 5 years after KT in prepubertal children. This may be at least partly related to their higher mean SDS at 2 and 5 years, which was slightly higher than those in our patient cohort.

Consequently, the percentage of patients with normal height reported from 0.5 to 0.7 SDS within 5 years after KT in prepubertal children. This may be at least partly related to their higher mean SDS at 2 and 5 years, which was slightly higher than those in our patient cohort. The main findings of our study suggest that catch-up growth after KT in young children (< 4 years) is mainly due to stimulated trunk growth and improved leg growth in older children, resulting in normalization of body height and proportions before puberty in the vast majority of patients. In addition, the pre-transplant period, congenital CKD, birth parameters, and parental height were significantly associated with growth in the pre-transplant period, congenital CKD, birth parameters, and parental height were significantly associated with growth. Although unadjusted growth data suggested superior post-transplant growth in patients with prior GH treatment, these differences were not significant in the multivariate analysis.
that improvements in body proportions are only to be expected in patients before pubertal age [26]. The latter finding is of importance as our previous analysis of growth after KT in a mixed cohort of prepubertal and pubertal children suggested that improvements in body proportions are only to be expected during pubertal age [13]. A reversible within-variation of organ systems or body segments as seen in the present study is called “phenotypic flexibility/plasticity” and seems to be of evolutionary benefit by allowing an individual to survive in case of deterioration of living conditions and enabling increased chances of reproduction after improved environmental conditions or illness, e.g., as seen here in children with CKD 5 undergoing KT [35, 36].

In the multivariable analysis, time after KT, allograft function, corticosteroid dosage, congenital CKD, birth parameters, and parental height were significantly associated with post-transplant growth, which is in line with previous studies [5, 9, 11–14, 37]. The average prednisolone dosage during the study period amounted to 3 mg/m² per day and steroid withdrawal was done in 18% of patients, only. Thus, a more vigorous steroid withdrawal or use of steroid-free free immunosuppressive protocols might have resulted in superior growth outcome as suggested by recent trials [11, 12, 14, 37].

Analysis of unadjusted data revealed superior growth outcome after (pre-emptive) living donor KT with respect to all linear body dimensions. However, this did not hold true after (pre-emptive) living donor KT with respect to all linear body dimensions. However, this did not hold true after (pre-emptive) living donor KT in the present study resembles the situation in healthy children where trunk growth precedes leg growth in early childhood resulting in both normalization of height and body proportions in the majority of patients before pubertal age [26]. The latter finding is of importance as our previous analysis of growth after KT in a mixed cohort of prepubertal and pubertal children suggested that improvements in body proportions are only to be expected during pubertal age [13]. A reversible within-variation of organ systems or body segments as seen in the present study is
| Parameter | Male | Female |
|-----------|------|--------|
| Height SDS | 0.097 | 0.031 |
| Leg length SDS | 0.009 | 0.005 |
| Sitting height SDS | 0.151 | 0.148 |
| Sitting height index SDS | 0.006 | 0.008 |

Table 4 Adjusted anthropometric parameters in subgroups of a cohort of 148 prepubertal kidney transplant recipients.

| Parameter | Male | Female |
|-----------|------|--------|
| Height SDS | 1.79 (1.26 to 2.31) | 1.90 (1.41 to 2.38) |
| Leg length SDS | 1.59 (1.08 to 2.10) | 1.73 (1.21 to 2.26) |
| Sitting height SDS | 1.73 (1.21 to 2.26) | 1.73 (1.21 to 2.26) |
| Sitting height index SDS | 1.73 (1.21 to 2.26) | 1.73 (1.21 to 2.26) |

Data are presented as estimated marginal means (95% confidence intervals); SDS, standardized scores; KT, kidney transplantation. GH, growth hormone.

growth at the time of KT in these patients [5, 6, 9, 15]. Nevertheless, (pre-emptive) living donor KT remains the treatment of choice in children with CKD 5 due to its superior outcome with respect to neurocognitive development, quality of life, and cardiovascular health [38–40].

It is our policy to apply GH treatment in all children with CKD stages 3–5D presenting with persistent growth failure based on current guidelines [1, 41]. Consequently 34% of our patients attaining CKD 5 at young age (2.8 years) were started on GH prior to KT, but stopped in all patients at the time of transplantation. It was hypothesized that this approach may impact on post-transplant growth [1]. Here we could clearly demonstrate that GH treatment in the pre-transplant period is significantly associated with superior growth outcomes after KT (increase in height, 0.47 SDS; leg length, 0.49; sitting height, 0.36 SDS) even after adjustment for confounders, supporting the vigorous use of GH in short children with CKD [1, 41–43].

Our study has several limitations and strengths. First, the number of patients in some subgroups was rather small. Second, due to the low frequency of GH use in the post-transplant period (4%), this parameter could not be incorporated in the multivariate analysis. Third, socioeconomic status which has been shown to be associated with treatment adherence and patient outcome after KT could not be addressed in the present study [44]. Fourth, several other parameters potentially affecting growth before and/or after KT, such as age at onset of CKD and years during significant growth impacting CKD, parathyroid hormone, albumin and sodium levels, and data on nutritional adequacy could not be addressed in our study. However, the prospective comprehensive anthropometric assessment, collection of major biochemical and clinical parameters, exclusion of pubertal patients, and long follow-up enabled us to analyze the age-dependent impact of KT on body dimensions and proportion and its determinants independent of main confounders.

In conclusion, catch-up growth after KT is mainly due to stimulated trunk growth in young children (<4 years), and improved leg growth in older children, resulting in normalization of body height and proportions until pubertal age in the vast majority of patients. Beside transplant function, steroid exposure and use of GH in the pre-transplant period are the main potentially modifiable factors associated with better growth potential after KT. Therefore, clinical management should focus on these factors. In addition, given risk factors for poor growth outcome like abnormal birth history, congenital CKD, and low parental height should be taken in account when rendering a decision whether to initiate such growth-promoting measures in order to maximize growth outcomes.

Acknowledgments We thank the patients and their families taking part in this study and appreciate the support of doctors and nurses responsible for patient care.
Author's contributions MŽ, JG, RR, DH, and UQ designed the study and interpreted the data. MŽ performed anthropometric measurements. JG, RR, KJ, and MŽ collected clinical data. MŽ, JG, and LP performed the statistical analysis. MŽ, JG, LP, RR, and DH revised, analyzed, and interpreted data. MŽ, JG, and DH wrote the first draft of the manuscript. All authors critically reviewed the manuscript and approved the final version for publication.

Funding Open Access funding enabled and organized by Projekt DEAL. This study was supported by a research grant from Hexal AG, Holzkirchen, Germany. The funder had no influence on the content of this study.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material, the material is protected by copyright and you may not use it without permission. For attribution, please indicate “Published by Springer.”

References

1. Drube J, Wan M, Bonthuis M, Wühl E, Bacchetta J, Santos F, Grenda R, Edefonti A, Harambat J, Shroff R, Tönshoff B, Haffiner D, European Society for Paediatric Nephrology Chronic Kidney Disease Mineral and Bone Disorders, Dialysis, and Transplantation Working Groups (2019) Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat Rev Nephrol 15:577–589

2. Franke D, Winkel S, Gellermann J, Querfeld U, Pape L, Ehrich JH, Haffiner D, Pavicic L, Zivicnjak M (2013) Growth and maturation improvement in children on renal replacement therapy over the past 20 years. Pediatr Nephrol 28:2043–2051

3. Harambat J, Bonthuis M, van Stralen KJ, Ariecta G, Battelino N, Bjerre A, Jahnkainen T, Lenov Y, Reusz G, Sandes AR, Sinha MD, Groothoff JW, Combe C, Jager KJ, Verrina E, Schaefer F, for the ESPN/ERA-EDTA Registry (2013) Adult height in patients with advanced CKD requiring renal replacement therapy during childhood. Clin J Am Soc Nephrol 9:92–99

4. Al-Uzri A, Matheson M, Gipson DS, Mendley SR, Hooper SR, Yadin O, Rozanovsky DJ, Moxey-Mims M, Furth SL, Warady BA, Gerson AC, Chronic Kidney Disease in Children Study Group (2013) The impact of short stature on health-related quality of life in children with chronic kidney disease. J Pediatr 163:736–41.e1

5. Fine RN, Martz K, Stablein D (2010) What have 20 years of data from the north american pediatric renal transplant cooperative study taught us about growth following renal transplantation in infants, children, and adolescents with end-stage renal disease? Pediatr Nephrol 25:739–746

6. Chua A, Cramer C, Moudgil A, Martz K, Smith J, Blydt-Hansen T, Neu A, Dhamidharka VR, NAPRTCS investigators (2019) Kidney transplant practice patterns and outcome benchmarks over 30 years: the 2018 report of the NAPRTCS. Pediatr Transplant 23:e1599

7. Ku E, Fine RN, Hsu CY, McCulloch C, Gilidven D, Grimes B, Johansen KL (2016) Height at first RRT and mortality in children. Clin J Am Soc Nephrol 11:832–839

8. Wong CS, Gipson DS, Gillen DL, Emerson S, Koepsell T, Sherrard DJ, Watkins SL, Stehman-Breen C (2000) Anthropometric measures and risk of death in children with end-stage renal disease. Am J Kidney Dis 36:811–819

9. Bonthuis M, Groothoff JW, Ariecta G, Baiko S, Battelino N, Bjerre A, Cransberg K, Kolvek G, Maxwell H, Mitteva P, Molechanova MS, Neuhaus TJ, Pape L, Reusz G, Rouset-Rouviere C, Sandes AR, Topaloglu R, Van Dyck M, Yilmen E, Zagozdzon I, Jager KJ, Harambat J (2020) Growth patterns after kidney transplantation in European children over the past 25 years: an ESPN/ERA-EDTA registry study. Transplantation 104:137–144

10. Winterberg PD, Garro R (2019) Long-term outcomes of kidney transplantation in children. Pediatr Clin N Am 66:269–280

11. Webb NJ, Douglas SE, Rajai A, Roberts SA, Grenda R, Marks SD, Watson AR, Fitzpatrick M, Vondrak K, Maxwell H, Jaray J, Van Damme-Lombaerts R, Milford DV, Godefroid N, Cochat P, Ogjanovic M, Murer L, McCulloch M, Tonshoff B (2015) Corticosteroid-free kidney transplantation improves growth: 2-year follow-up of the TWIST randomized controlled trial. Transplantation 99:1178–1185

12. Tsampalieros A, Knoll GA, Molnar AO, Fergusson N, Fergusson DA (2017) Corticosteroid use and growth after pediatric solid organ transplantation: a systematic review and meta-analysis. Transplantation 101:694–703

13. Franke D, Thomas L, Steffens R, Pavičić L, Gellermann J, Froede K, Querfeld U, Haffiner D, Zivicnjak M (2015) Patterns of growth after kidney transplantation among children with ESRD. Clin J Am Soc Nephrol 10:127–134

14. Sarwal MM, Ettinger RB, Dhamidharka V, Benfield M, Mathias R, Portale A, McDonald R, Harmon W, Karram D, Vehaskari VM, Kamil E, Baluarte HJ, Warady B, Tang L, Liu J, Li L, Naesens M, Sigdel T, Waskerwitz J, Salvaterra O (2012) Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up. Am J Transplant 12:2719–2729

15. Pape L, Ehrich JH, Zivicnjak M, Offner G (2005) Growth in children after kidney transplantation with living related donor graft or cadaveric graft. Lancet 366:151–153

16. Greenbaum LA, Munoz A, Schneider MF, Kaskell FJ, Askenazi DJ, Jenkins R, Hotchkiss H, Moxey-Mims M, Furth SL, Warady BA (2011) The association between abnormal birth history and growth in children with CKD. Clin J Am Soc Nephrol 6:14–21

17. Franke D, Alakan H, Pavicic L, Gellermann J, Muller D, Querfeld U, Haffiner D, Zivicnjak M (2013) Birth parameters and parental height predict growth outcome in children with chronic kidney disease. Pediatr Nephrol 28:2335–2341

18. Franke D, Volker S, Haase S, Pavicic L, Querfeld U, Ehrich JH, Zivicnjak M (2010) Prematurity, small for gestational age and perinatal parameters in children with congenital, hereditary and acquired chronic kidney disease. Nephrol Dial Transplant 25:3918–3924

19. Franke D, Steffens R, Thomas L, Pavicic L, Ahlenstiel T, Pape L, Gellermann J, Muller D, Querfeld U, Haffiner D, Zivicnjak M (2017) Kidney transplantation fails to provide adequate growth in children with chronic kidney disease born small for gestational age. Pediatr Nephrol 32:511–519

20. Zivicnjak M, Franke D, Filler G, Haffiner D, Froede K, Nissel R, Haase S, Offner G, Ehrich JH, Querfeld U (2007) Growth
impairment shows an age-dependent pattern in boys with chronic kidney disease. Pediatr Nephrol 22:420–429

21. De Souza VC, Rabilloud M, Cochat P, Serléste, H, Hadji-Aissa A, Kassai B, Ranchin B, Berg U, Herthalien M, Dubourg L (2012) Schwartz formula: is one k-coefficient adequate for all children? PLoS One 7:e53439

22. Voigt M, Schneider KT, Jährig K (1996) Analysis of a 1992 birth sample in Germany. 1: new percentile values of the body weight of newborn infants. Geburtshilfe Frauenheilkd 56:550–558

23. Visiaccnjak M, Schnabel D, Staude H, Even G, Marx M, Beetz R, Hrenovic J (1981) Practical human biology. Academic Press, London

24. Weiner J, Lourie J (1981) Practical human biology. Academic Press, London

25. Visiaccnjak M, Nzivotovska L, Franke D, Hrenovic J, Bisof V (2003) Generalized growth patterns for stature, sitting height and limbs length in croatian children and youth (3 to 18 years of age). Coll Antropol 27:321–334

26. Visiaccnjak M, Sirovicza L, Frende J, Hrenovic J, Bisof V (2003) Gender-specific growth patterns for stature, sitting height and limbs length in croatian children and youth (3 to 18 years of age). Coll Antropol 27:321–334

27. Visiaccnjak M, Smolcic Narancic N, Sirovicza L, Franke D, Hrenovic J, Bisof V, Tomaz, Z, Skaric-Juretic T (2008) Gender-specific growth patterns of transversal body dimensions in croatian children and youth (2 to 18 years of age). Coll Antropol 32:419–431

28. Visiaccnjak M, Franke D, Zenker M, Hoyer J, Lucke T, Pape L, Ehrich JH (2009) SMARCA1 mutations: a cause of prepubertal idiopathic steroid-resistant nephrotic syndrome. Pediatri Res 65:564–568

29. Delvecchio M, Cavallo L (2010) Growth and endocrine function in thalassemia major in childhood and adolescence. J Endocrinol Invest 33:61–68

30. Mazzanti L, Matteucci C, Scarano E, Tamburrino F, Ragni MC, Cicognani A (2010) Auxological and anthropometric evaluation in skeletal dysplasias. J Endocrinol Invest 33:19–25

31. Malaquias AC, Scalco RC, Fontenele EG, Costalonga EF, Baldin AD, Braz AF, Funari MF, Nishi MY, Guerra-Junior G, Mendonca BB, Arnhold IJ, Jorge AA (2013) The sitting height/height ratio for age in healthy and short individuals and its potential role in selecting short children for SHOX analysis. Horm Res Paediatr 08:449–456

32. Nissel R, Brazda I, Feneberg R, Wigger M, Greiner C, Querfeld U, Haffner D (2004) Effect of renal transplantation in childhood on longitudinal growth and adult height. Kidney Int 66:792–800

33. Shaw V, Polderman N, Renken-Terhaerdt J, Paglialonga F, Oosterveld M, Tuokkokola J, Anderson C, Desloovere A, Greenbaum L, Haffner D, Nelms C, Qizilbash L, Vande Walle J, Warady B, Shroff R, Rees L (2020) Energy and protein requirements for children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the pediatric renal nutrition taskforce. Pediatr Nephrol 35:519–531

34. Behnisch R, Kirchner M, Anarat A, Bacchetta J, Shroff R, Bilginer Y, Mir S, Caliskan S, Paripovic D, Harambat J, Mencarelli F, Büscher R, Arbeiter K, Soylemezoglu O, Zaloszyc A, Zuwowska A, Melk A, Querfeld U, Schaefer F, 4C Study Consortium (2019) Determinants of statural growth in European children with chronic kidney disease: findings from the cardiovascular comorbidity in children with chronic kidney disease (4C) study. Front Pediatr 7:278

35. Price TD, Vvarnstrom A, Irwin DE (2003) The role of phenotypic plasticity in driving genetic evolution. Proc Biol Sci 270:1433–1440

36. Piersma T, Drent J (2003) Phenotypic flexibility and the evolution of organisinal design. Trends Ecol Evol 18:228–233

37. Grenda R, Watson A, Trompeter R, Tonshoff B, Ray J, Fitzpatrick M, Murer L, Vondrak K, Maxwell H, van Damme-Lombaerts R, Loirat C, Mor E, Cochat P, Milford DV, Brown M, Webb NJ (2010) A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. Am J Transplant 10:828–836

38. Hartmann H, Hawellek N, Wedeink M, Vogel C, Das AM, Balonwu K, Ehrich JH, Haffner D, Pape L (2015) Early kidney transplantation improves neurocognitive outcome in patients with severe congenital chronic kidney disease. Transpl Int 28:429–436

39. Bertram JF, Goldstein SL, Pape L, Schaefer F, Shroff RC, Warday BA (2016) Kidney disease in children: latest advances and remaining challenges. Nat Rev Nephrol 12:182–191

40. Schmidt BMW, Sugianto RI, Thurm D, Azukaitis K, Bayazit AK, Canpolat N, Erolgu AG, Caliskan S, Doyon A, Duzova A, Karagöz T, Anarat A, Deveci M, Mir S, Ranchin B, Shroff R, Baskin E, Litwin M, Ozcakar ZB, Buscher R, Soylemezoglu O, Dusek J, Kemper MJ, Matteucci MC, Habbig S, Laube G, Wuhl E, Querfeld U, Sander A, Schaefer F, Melk A, 4C Study Consortium (2018) Early effects of renal replacement therapy on cardiovascular comorbidity in children with end-stage kidney disease: Findings from the 4C-1 study. Transplantation 102:484–492

41. Mahan JD, Warday BA, Consensus Committee (2006) Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatr Nephrol 21:917–930

42. Akchurin OM, Kogon AJ, Kumar J, Sethna CB, Hammad HT, Greenbaum LA, Furth SL, Moxey-Mims M, Warady BA (2016) Kidney disease in children: latest advances and remaining challenges. Pediatr Nephrol 31:1011–1019

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.